

FACSIMILE COVER SHEET

**SALIWANCHIK, LLOYD & SALIWANCHIK**  
A Professional Association  
P.O. Box 142950  
Gainesville, FL 32614-2950

**RECEIVED**  
**CENTRAL FAX CENTER**  
**APR 24 2006**

Telephone (352) 375-8100  
Facsimile (352) 372-5800

---

**TO:** Examiner Shahnam J. Sharareh **FROM:** Frank C. Eisenschenk, Ph.D.  
**COMPANY:** U.S. Patent Office, Art Unit 1617 **DATE:** April 24, 2006  
**FAX NO.:** 1-571-273-8300 **NO. OF PAGES:** 30  
**(INCLUDING COVER SHEET)**

---

**SUBJECT/MESSAGE:**

Re: U.S. Patent Application Docket No. MET-037CXT  
COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS  
USEFUL FOR THE TREATMENT OF DIABETES  
(van Poelje, Erion, Fujiwara)  
Serial No. 09/900,364; filed July 5, 2001

Attachment: Election Under 35 U.S.C. § 121 (29 pages)

**THIS IS AN OFFICIAL DOCUMENT.**  
**PLEASE DELIVER IMMEDIATELY.**

---


*The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.*

---

*If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.*

J:\MET\037CXT\Fax\Examiner.doc\DNB/sl

I hereby certify that this correspondence is being  
facsimile transmitted to the United States Patent  
and Trademark Office on April 24, 2006.

  
Frank C. Eisenschenk, Ph.D., Patent Attorney

ELECTION UNDER 35 U.S.C. § 121  
Examining Group 1617  
Patent Application  
Docket No. MET-037CXT  
Serial No. 09/900,364

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**RECEIVED**  
**CENTRAL FAX CENTER**

**APR 24 2006**

Examiner : Shahnam J. Sharareh  
Art Unit : 1617  
Applicants : Paul D. van Poelje, Mark D. Erion, Toshihiko Fujiwara  
Serial No. : 09/900,364  
Filed : July 5, 2001  
Conf. No. : 7049  
For : Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the  
Treatment of Diabetes

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

ELECTION UNDER 35 U.S.C. § 121

Sir:

In response to the written Restriction Requirement dated February 24, 2006 in the above-  
identified patent application, Applicants hereby elect to prosecute the following:

J:\MET\037CXT\Amend-Resp\Election.doc\DNB/sl

2

Docket No. MET-037CXT  
Serial No. 09/900,364

With respect to insulin secretagogues, Applicants elect sulfonylurea antidiabetic agents, with a further election of glyburide as the specific specie elected within this group of compounds. As the ultimate species of FBPase inhibitor, Applicants hereby elect Compound J (identified at page 300 of this application). Compound J corresponds to a compound within Formula I.

